BeOne Medicines Ltd. Class A 688235

BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track record against a less clear-cut value case. BeOne Medicines is up 86.0% over three years, which makes the stock more dependent on whether the business can now justify that stronger share price profile. FDA...

BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination of first-in-class immunotherapy approval and U.S. tariff exemption tied to onshoring commitments reshapes BeOne’s positioning in cancer care and its cost base in a key...

BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing more than $1 billion of U.S. manufacturing investment, including a $300 […]

SAN CARLOS, Calif., August 31, 2026--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scient

SAN CARLOS, Calif., August 31, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstr

There are solid gains to knowledge workers. But smaller ones outside it.

Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors? Let's find out.

SAN CARLOS, Calif., August 25, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction,

Is it a good or bad thing when a stock experiences a golden cross technical event?

SAN CARLOS, Calif. & SEATTLE, August 18, 2026--BeOne Medicines Ltd. ("BeOne") (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with t

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution’s four clinical-stage RAS(ON) inhibitors to evaluate novel combination therapies for RAS-addicted cancers. Crucially, BeOne acquired exclusive rights […]

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

SAN CARLOS, Calif. & REDWOOD CITY, Calif., August 10, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution

BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the company lifting its full year 2026 outlook. See our latest analysis for BeOne Medicines. These results sit against a share price that has gained 6.8% over the past month and 6.0% year to date, while the 3 year total shareholder return of 66.6% points to sustained investor confidence in BeOne Medicines. If BeOne Medicines caught your...

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued to expand across approved indications and global markets. Chief Executive Officer John Oyler said t

SAN CARLOS, Calif., August 05, 2026--BeOne Medicines Ltd. announced financial results and corporate updates from the second quarter of 2026.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.